Search Results - "Iveson, T"

Localised colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up by Argilés, G., Tabernero, J., Labianca, R., Hochhauser, D., Salazar, R., Iveson, T., Laurent-Puig, P., Quirke, P., Yoshino, T., Taieb, J., Martinelli, E., Arnold, D.

“…•This ESMO Clinical Practice Guideline provides key recommendations on the management of localised colon cancer.•Authorship includes a multidisciplinary group…”
Get full text

Management of advanced colorectal cancer: state of the art by SAUNDERS, M, IVESON, T

“…Colorectal cancer (CRC) caused over 500 000 deaths worldwide in 2002. Recent advances in the treatment of advanced disease include the incorporation of two new…”
Get full text

Gemcitabine alone or in combination with cisplatin in patients with advanced or metastatic cholangiocarcinomas or other biliary tract tumours: a multicentre randomised phase II study - The UK ABC-01 Study by Valle, J W, Wasan, H, Johnson, P, Jones, E, Dixon, L, Swindell, R, Baka, S, Maraveyas, A, Corrie, P, Falk, S, Gollins, S, Lofts, F, Evans, L, Meyer, T, Anthoney, A, Iveson, T, Highley, M, Osborne, R, Bridgewater, J

“…Background: We assessed the activity of gemcitabine (G) and cisplatin/gemcitabine (C/G) in patients with locally advanced (LA) or metastatic (M) (advanced)…”
Get full text

Oxaliplatin and 5-FU/folinic acid (modified FOLFOX6) with or without aflibercept in first-line treatment of patients with metastatic colorectal cancer: the AFFIRM study by Folprecht, G., Pericay, C., Saunders, M.P., Thomas, A., Lopez Lopez, R., Roh, J.K., Chistyakov, V., Höhler, T., Kim, J.-S., Hofheinz, R.-D., Ackland, S.P., Swinson, D., Kopp, M., Udovitsa, D., Hall, M., Iveson, T., Vogel, A., Zalcberg, J.R.

“…The combination of aflibercept with FOLFIRI has been shown to significantly prolong overall survival in patients with metastatic colorectal cancer (mCRC) after…”
Get full text

The hard road to data interpretation: 3 or 6 months of adjuvant chemotherapy for patients with stage III colon cancer? by Sobrero, A., Grothey, A., Iveson, T., Labianca, R., Yoshino, T., Taieb, J., Maughan, T., Buyse, M., André, T., Meyerhardt, J., Shields, A.F., Souglakos, I., Douillard, J.-Y., Cervantes, A.

“…Six months of adjuvant oxaliplatin-based chemotherapy is standard for patients with stage III colon cancer following surgery. However, oxaliplatin is…”
Get full text

Bevacizumab with peri-operative epirubicin, cisplatin and capecitabine (ECX) in localised gastro-oesophageal adenocarcinoma: a safety report by Okines, A.F.C., Langley, R.E., Thompson, L.C., Stenning, S.P., Stevenson, L., Falk, S., Seymour, M., Coxon, F., Middleton, G.W., Smith, D., Evans, L., Slater, S., Waters, J., Ford, D., Hall, M., Iveson, T.J., Petty, R.D., Plummer, C., Allum, W.H., Blazeby, J.M., Griffin, M., Cunningham, D.

“…Peri-operative chemotherapy and surgery is a standard treatment of localised oesophagogastric adenocarcinoma; however, the outcomes remain poor. ST03 is a…”
Get full text

Prospective Randomized Trial Comparing Mitomycin, Cisplatin, and Protracted Venous-Infusion Fluorouracil (PVI 5-FU) With Epirubicin, Cisplatin, and PVI 5-FU in Advanced Esophagogastric Cancer by ROSS, P, NICOLSON, M, LOFTS, F, NORMAN, A, CUNNINGHAM, D, VALLE, J, SEYMOUR, M, HARPER, P, PRICE, T, ANDERSON, H, IVESON, T, HICKISH, T

“…We report the results of a prospectively randomized study that compared the combination of epirubicin, cisplatin, and protracted venous-infusion fluorouracil…”
Get full text

Hand-foot syndrome is a biomarker of improved survival following treatment with capecitabine by Jandu, H., Church, D., Paul, J., Tomlinson, I., Iveson, T., Kerr, R., Kerr, D., Palles, C.

Get full text

The association of clinical and patient factors with chemotherapy-induced peripheral neuropathy (CIPN) in colorectal cancer: Secondary analysis of the SCOT trial by Lemanska, A., Harkin, A., Iveson, T., Kelly, C., Saunders, M., Faithfull, S.

“…Chemotherapy-induced peripheral neuropathy (CIPN) is a common adverse effect of oxaliplatin. CIPN can impair long-term quality of life and limit the dose of…”
Get full text

Exposure-response analysis of rilotumumab in gastric cancer: the role of tumour MET expression by Zhu, M, Tang, R, Doshi, S, Oliner, K S, Dubey, S, Jiang, Y, Donehower, R C, Iveson, T, Loh, E Y, Zhang, Y

“…Background: Rilotumumab, an investigational, monoclonal antibody, inhibits MET-mediated signalling. In a randomized phase 2 trial of…”
Get full text

Phase III Double-Blind Placebo-Controlled Study of Farnesyl Transferase Inhibitor R115777 in Patients With Refractory Advanced Colorectal Cancer by RAO, S, CUNNINGHAM, D, ILLES, A, BELLY, R, PEREZ-RUIXO, J. J, PARK, Y. C, PALMER, P. A, DE GRAMONT, A, SCHEITHAUER, W, SMAKAL, M, HUMBLET, Y, KOURTEVA, G, IVESON, T, ANDRE, T, DOSTALOVA, J

“…To determine whether R115777 improves survival in patients with refractory advanced colorectal cancer (CRC) in a multicenter, double-blind, prospective…”
Get full text

Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial by Douillard, JY, Cunningham, D, Roth, AD, Navarro, M, James, RD, Karasek, P, Jandik, P, Iveson, T, Carmichael, J, Alakl, M, Gruia, G, Awad, L, Rougier, P

“…Irinotecan is active against colorectal cancer in patients whose disease is refractory to fluorouracil. We investigated the efficacy of these two agents…”
Get full text

Presence of digital dermatitis treponemes on cattle and sheep hoof trimming equipment by Sullivan, L. E., Blowey, R. W., Carter, S. D., Duncan, J. S., Grove-White, D. H., Page, P., Iveson, T., Angell, J. W., Evans, N. J.

“…Digital dermatitis (DD) is an infectious foot disease causing severe lameness in dairy cattle (worldwide) and sheep (UK). This study investigated whether DD…”
Get full text

Report of two protocol planned interim analyses in a randomised multicentre phase III study comparing capecitabine with fluorouracil and oxaliplatin with cisplatin in patients with advanced oesophagogastric cancer receiving ECF by SUMPTER, K, HARPER-WYNNE, C, HILL, M, OATES, J, CUNNINGHAM, D, RAO, S, TEBBUTT, N, NORMAN, A. R, WARD, C, IVESON, T, NICOLSON, M, HICKISH, T

“…The purpose of the study was to establish the optimal dose of capecitabine (X) to be used within a multicentre, randomised study evaluating the potential roles…”
Get full text

A randomised comparison between 6 months of bolus fluorouracil/leucovorin and 12 weeks of protracted venous infusion fluorouracil as adjuvant treatment in colorectal cancer by Chau, I., Norman, A. R., Cunningham, D., Tait, D., Ross, P. J., Iveson, T., Hill, M., Hickish, T., Lofts, F., Jodrell, D., Webb, A., Oates, J. R.

“…Background: We performed a multicentre randomised trial to compare the efficacy and toxicity of 12 weeks of protracted venous infusion (PVI) 5-fluorouracil…”
Get full text

A phase I study of sunitinib in combination with FOLFIRI in patients with untreated metastatic colorectal cancer by Starling, N., Vázquez-Mazón, F., Cunningham, D., Chau, I., Tabernero, J., Ramos, F.J., Iveson, T.J., Saunders, M.P., Aranda, E., Countouriotis, A.M., Ruiz-Garcia, A., Wei, G., Tursi, J.M., Guillen-Ponce, C., Carrato, A.

“…This study evaluated the maximum tolerated dose (MTD) of sunitinib, a multitargeted tyrosine kinase inhibitor, combined with FOLFIRI (irinotecan 180 mg/m2…”
Get full text

Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer by Webb, A, Cunningham, D, Scarffe, J H, Harper, P, Norman, A, Joffe, J K, Hughes, M, Mansi, J, Findlay, M, Hill, A, Oates, J, Nicolson, M, Hickish, T, O'Brien, M, Iveson, T, Watson, M, Underhill, C, Wardley, A, Meehan, M

“…We report the results of a prospectively randomized study that compared the combination of epirubicin, cisplatin, and protracted venous infusion fluorouracil…”
Get more information

The impact of primary tumour origins in patients with advanced oesophageal, oesophago–gastric junction and gastric adenocarcinoma—individual patient data from 1775 patients in four randomised controlled trials by Chau, I., Norman, A.R., Cunningham, D., Oates, J., Hawkins, R., Iveson, T., Nicolson, M., Harper, P., Seymour, M., Hickish, T.

“…It is unclear if differential chemotherapy effects exist on overall survival (OS), response rate (RR) and toxicity depending on primary tumour origin…”
Get full text

Efficacy and tolerability of chemotherapy in elderly patients with advanced oesophago-gastric cancer: A pooled analysis of three clinical trials by Trumper, M., Ross, P.J., Cunningham, D., Norman, A.R., Hawkins, R., Seymour, M., Harper, P., Iveson, T., Nicolson, M., Hickish, T.

“…The aim of this study was to determine the benefits of chemotherapy for oesophago-gastric cancer (OGC) in patients 70 years and above (⩾70) in comparison to…”
Get full text

Twelve weeks of protracted venous infusion of fluorouracil (5-FU) is as effective as 6 months of bolus 5-FU and folinic acid as adjuvant treatment in colorectal cancer by SAINI, A, NORMAN, A. R, ROSS, P. J, OATES, J, CUNNINGHAM, D, CHAU, I, HILL, M, TAIT, D, HICKISH, T, IVESON, T, LOFTS, F, JODRELL, D

“…We performed a multicentre randomised trial to compare the efficacy and toxicity of 12 weeks of 5-fluorouracil (5-FU) delivered by protracted intravenous…”
Get full text